BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Yoo HJ, Harapan BN. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. Immunol Res 2021;69:471-86. [PMID: 34554405 DOI: 10.1007/s12026-021-09236-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bravo-Pérez C, Sola M, Teruel-Montoya R, García-Malo MD, Ortuño FJ, Vicente V, de Arriba F, Jerez A. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers (Basel) 2021;13:4332. [PMID: 34503142 DOI: 10.3390/cancers13174332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Battram AM, Bachiller M, Lopez V, Fernández de Larrea C, Urbano-Ispizua A, Martín-Antonio B. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers (Basel) 2021;13:3534. [PMID: 34298748 DOI: 10.3390/cancers13143534] [Reference Citation Analysis]
4 Olnes MJ. Immune Therapies for Hematologic Malignancies. Cancers (Basel) 2021;13:295. [PMID: 33467389 DOI: 10.3390/cancers13020295] [Reference Citation Analysis]
5 Martino M, Paviglianiti A. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opin Biol Ther 2021;21:1025-34. [PMID: 33412948 DOI: 10.1080/14712598.2021.1872540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhai B, Liu X, Xu Y, Zhu G, Zhou S, He Y, Wang X, Su W, Han G, Wang R. Single-cell atlas of splenocytes reveals a critical role of a novel plasma cell‒specific marker Hspa13 in antibody class-switching recombination and somatic hypermutation. Mol Immunol 2021;141:79-86. [PMID: 34837777 DOI: 10.1016/j.molimm.2021.11.014] [Reference Citation Analysis]
7 Sgherza N, Curci P, Rizzi R, Musto P. Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor. Front Oncol 2021;11:716751. [PMID: 34660279 DOI: 10.3389/fonc.2021.716751] [Reference Citation Analysis]
8 Byun JM, Kim SA, Koh Y, Shin DY, Kwon JH, Kim JS, Kim K, Min CK, Eom HS, Lee JJ, Bang SM, Yoon SS. Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. Curr Probl Cancer 2021;:100786. [PMID: 34481658 DOI: 10.1016/j.currproblcancer.2021.100786] [Reference Citation Analysis]
9 Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context 2021;10:2021-2-4. [PMID: 34603459 DOI: 10.7573/dic.2021-2-4] [Reference Citation Analysis]
10 Simmons GL, Satta T, Castaneda Puglianini O. Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol 2021;34:101306. [PMID: 34625232 DOI: 10.1016/j.beha.2021.101306] [Reference Citation Analysis]
11 Newport EL, Pedrosa AR, Njegic A, Hodivala-Dilke KM, Muñoz-Félix JM. Improved Immunotherapy Efficacy by Vascular Modulation. Cancers (Basel) 2021;13:5207. [PMID: 34680355 DOI: 10.3390/cancers13205207] [Reference Citation Analysis]
12 Yang Y, Liu L, Guo Z, Huang J, Li L, Shao Y, Song M, Yang A, Sun B. A novel computer vision-based assessment of neutrophil chemotaxis in patients with severe infection. Clin Transl Immunology 2021;10:e1333. [PMID: 34434554 DOI: 10.1002/cti2.1333] [Reference Citation Analysis]
13 Legarda MA, Cejalvo MJ, de la Rubia J. Recent Advances in the Treatment of Patients with Multiple Myeloma. Cancers (Basel) 2020;12:E3576. [PMID: 33265952 DOI: 10.3390/cancers12123576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv 2021:2021. [PMID: 34013294 DOI: 10.1101/2021.05.10.21256634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol 2021. [PMID: 34472091 DOI: 10.1111/bjh.17805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sun M, Xu P, Wang E, Zhou M, Xu T, Wang J, Wang Q, Wang B, Lu K, Wang C, Chen B. Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL. Mol Ther Oncolytics 2021;23:96-106. [PMID: 34703879 DOI: 10.1016/j.omto.2021.08.014] [Reference Citation Analysis]
17 Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol 2022;18:277-89. [PMID: 34854741 DOI: 10.2217/fon-2021-1090] [Reference Citation Analysis]
18 Jin X, Lu W, Zhang M, Xiong X, Sun R, Wei Y, He X, Zhao M. Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology. Front Immunol 2021;12:638907. [PMID: 33953713 DOI: 10.3389/fimmu.2021.638907] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ Jr, Melenhorst JJ. Engineering enhanced CAR T-cells for improved cancer therapy. Nat Cancer 2021;2:780-93. [PMID: 34485921 DOI: 10.1038/s43018-021-00241-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunology 2021;10:e1274. [PMID: 33959279 DOI: 10.1002/cti2.1274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Powell K, Russler-Germain D, Prasad V. Idecabtagene vicleucel: questions regarding the appropriate role and cost. Br J Haematol 2021. [PMID: 34402527 DOI: 10.1111/bjh.17784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Hansen DK, Dam M, Faramand RG. Toxicities associated with adoptive cellular therapies. Best Pract Res Clin Haematol 2021;34:101287. [PMID: 34625233 DOI: 10.1016/j.beha.2021.101287] [Reference Citation Analysis]
23 Maiolino A, Costa LJ, Pasquini M, Crusoe EQ, Vigorito AC, Salvino MA, Seguro FS, Filho JS, Hungria VTM. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. Hematol Transfus Cell Ther 2021;43 Suppl 2:S30-4. [PMID: 34794794 DOI: 10.1016/j.htct.2021.09.004] [Reference Citation Analysis]
24 Mansouri V, Yazdanpanah N, Rezaei N. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. Int Rev Immunol 2021;:1-20. [PMID: 34607523 DOI: 10.1080/08830185.2021.1984449] [Reference Citation Analysis]
25 Wang H, Wang L, Li Y, Li G, Zhang X, Jiang D, Zhang Y, Liu L, Chu Y, Xu G. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells. Cancer Cell Int 2021;21:450. [PMID: 34429118 DOI: 10.1186/s12935-021-02151-z] [Reference Citation Analysis]
26 Wang B, Rajeeve S, Madduri D. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight. Cancer J 2021;27:205-12. [PMID: 34549909 DOI: 10.1097/PPO.0000000000000525] [Reference Citation Analysis]
27 Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, Li J, Chen L. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med 2021;53:1547-59. [PMID: 34459681 DOI: 10.1080/07853890.2021.1970218] [Reference Citation Analysis]
28 Wang Y, Zu C, Teng X, Yang L, Zhang M, Hong R, Zhao H, Cui J, Xu H, Hongsheng AC, Hu Y, Huang H. BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement. J Immunother 2022;45:25-34. [PMID: 34874329 DOI: 10.1097/CJI.0000000000000391] [Reference Citation Analysis]
29 Shen M, Chen T. Mesenchymal Stem Cell-Derived Exosomes and Their Potential Agents in Hematological Diseases. Oxid Med Cell Longev 2021;2021:4539453. [PMID: 34621464 DOI: 10.1155/2021/4539453] [Reference Citation Analysis]
30 Wilhite D, Arfa A, Cotter T, Savage NM, Bollag RJ, Singh G. Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains. Pract Lab Med 2021;27:e00256. [PMID: 34703870 DOI: 10.1016/j.plabm.2021.e00256] [Reference Citation Analysis]
31 Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol 2021. [PMID: 34230645 DOI: 10.1038/s41571-021-00530-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Dholaria B, Savani BN, Huang XJ, Nagler A, Perales MA, Mohty M. The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. Br J Haematol 2021;193:1060-75. [PMID: 33928630 DOI: 10.1111/bjh.17460] [Reference Citation Analysis]
33 Nathwani N, Bertamini L, Banerjee R, Gay F, Shah N, Krishnan A. When and How to Treat Relapsed Multiple Myeloma. Am Soc Clin Oncol Educ Book 2021;41:358-75. [PMID: 34010043 DOI: 10.1200/EDBK_320129] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Pepple KL, Van Gelder RN. T-Cell Therapy to the Rescue. Ophthalmol Retina 2021;5:835-7. [PMID: 34503757 DOI: 10.1016/j.oret.2021.07.001] [Reference Citation Analysis]
35 Luo X, Xu J, Yu J, Yi P. Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer. Front Immunol 2021;12:692360. [PMID: 34248988 DOI: 10.3389/fimmu.2021.692360] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Aksenova AY, Zhuk AS, Lada AG, Zotova IV, Stepchenkova EI, Kostroma II, Gritsaev SV, Pavlov YI. Genome Instability in Multiple Myeloma: Facts and Factors. Cancers (Basel) 2021;13:5949. [PMID: 34885058 DOI: 10.3390/cancers13235949] [Reference Citation Analysis]
37 Hu A, Chen H, Liang J, Liu C, Li F, Mu C. Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow. J Control Release 2021;339:1-13. [PMID: 34536449 DOI: 10.1016/j.jconrel.2021.09.018] [Reference Citation Analysis]